The FDA granted approval to GlaxoSmithKline's new respiratory drug Breo Ellipta. By itself, that's a solid victory for GSK, which needs to build up its respiratory franchise before Advair copycats finally make their way to market. Analysts figure Breo for a blockbuster in the U.S., with peak sales at around $1.3 billion.
With two of its respiratory meds under review for potential approvals this year, Theravance stands to grow up significantly in 2013, giving more reasons for large pharma companies to come knocking. GlaxoSmithKline, Theravance's longtime lung drug partner and owner of 27% of the biotech's stock, rose again to the top of the list of potential acquirers in speculation this week. Read the full story >>
Drugmakers might keep the lights on with approvals of new drugs that offer marginal benefits, but pharma chiefs understand that only pioneering therapies pave the way to explosive growth. And GlaxoSmithKline's chairman of R&D has been touting the innovative and advanced nature of contenders in the drug giant's late-stage pipeline.
Harris Interactive has been digging into physicians' response to drug brands, therapeutic area by therapeutic area, racking up more evidence for an emotional variable in the doctor-drug trust equation.
Once again, Europe is dragging GlaxoSmithKline down. And this time, the drag was worse than expected: Sales in the region dropped by 9%. Together with a 6% decline in U.S. sales on generic competition, that was enough to push overall revenues down by 5%, to £6.54 billion, or $10.3 billion.
Some of the biggest blockbusters known to the pharma industry have dropped off the patent cliff and tumbled into the brutal land of generic therapies, where low-priced competition lays sales to...
GlaxoSmithKline has made progress with one piece of the puzzle to maintain its dominance in the respiratory drug market.
In no surprise to analysts, Novartis's QVA149 was the standout experimental drug to take the spotlight at the recent European Respiratory Society meeting in Vienna. Novartis may be delayed in the U.S. on this program, but GlaxoSmithKline hasn't been nearly as impressive with its own Relovair, a next-gen product intended to replace Advair, the top selling COPD drug.
Now that Plavix and Lipitor are down for the count, AstraZeneca's Nexium is the reigning heavyweight drug champion. According to Drugs.com, the stomach drug outsold all other branded drugs during the second quarter, with $1.38 billion in revenues. But Nexium's dominance could be short-lived.
GlaxoSmithKline generated positive results from a mid-stage trial for its experimental drug in patients with an uncommon form of asthma, giving the London drug giant confidence in advancing the program to Phase III development before the end of the year, Reuters reported.